Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 07:00 ET | Source: Tisento Therapeutics Inc

Tisento Therapeutics Announces Publication of MELAS Interview Study, Incorporating Patients’ Perspectives to Elucidate Symptoms and Impacts of Rare Mitochondrial Disease

Findings from Tisento's MELAS interview study were published in the Journal of Patient-Reported Outcomes.
August 20, 2025 07:00 ET | Source: Tisento Therapeutics Inc

First PRIZM Study Participant Enrolled in Tisento Therapeutics’ Open-Label Extension Study in MELAS

The first participant has enrolled in Tisento’s open-label extension study in MELAS, open to those who complete treatment in the PRIZM study.
June 17, 2025 07:00 ET | Source: Tisento Therapeutics Inc

Tisento Therapeutics Receives U.S. FDA Fast Track Designation for Zagociguat for the Treatment of MELAS

Tisento received U.S. FDA Fast Track designation for zagociguat for the treatment of MELAS.
May 14, 2025 07:00 ET | Source: Tisento Therapeutics Inc

Tisento Highlights Two Venues Advancing Patient-Focused Therapeutic Development for Mitochondrial Diseases

Tisento announces upcoming opportunities to optimize therapeutic development for mitochondrial diseases.
January 27, 2025 07:00 ET | Source: Tisento Therapeutics Inc

First Participant Dosed in Tisento Therapeutics’ Global Phase 2b PRIZM Study Evaluating Zagociguat for the Treatment of MELAS

The first patient has been dosed in Tisento's global Phase 2b PRIZM study investigating zagociguat in MELAS.
October 25, 2023 08:00 ET | Source: Tisento Therapeutics Inc

Tisento Therapeutics Initiates Interview Study with Individuals with MELAS to Elucidate the Symptoms and Impact of Disease and Inform the Zagociguat Clinical Development Program

Tisento Therapeutics Initiates Interview Study with Individuals with MELAS to Elucidate the Symptoms and Impact of Disease and Inform the Zagociguat Clinic